Home > Insider Trading > Filing (0000899243-15-007336)

Filing Details

Accession Number:: 0000899243-15-007336
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-10-30 16:15:24
Reporting Period:: 2015-10-28

Filing Date:: 2015-10-30
Accepted Time:: 2015-10-30 16:15:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1466301	Clovis Oncology Inc.	CLVS	Pharmaceutical Preparations (2834)	900475355

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1650504	Lindsey Rolfe	C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-10-28	4,000	$3.08	4,000	No	4	M	Direct
Common Stock	Disposition	2015-10-28	500	$95.78	3,500	No	4	S	Direct
Common Stock	Disposition	2015-10-28	1,300	$97.31	2,200	No	4	S	Direct
Common Stock	Disposition	2015-10-28	1,962	$98.91	238	No	4	S	Direct
Common Stock	Disposition	2015-10-28	238	$99.22	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee stock option (right to buy)	Disposition	2015-10-28	4,000	$0.00	4,000	$3.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
23,034		2020-04-07	No	4	M	Direct

Footnotes

This transaction was executed in multiple trades at prices ranging from $95.365 to $96.300 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $97.000 to $97.920 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $98.120 to $99.120 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $99.150 to $99.290 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2015.
The option vested as to 25% of the shares on April 1, 2011, and the remainder vested in substantially equal installments over the 36 months immediately following such date.